Gary Pigeau received his Ph.D. in Biotechnology from Brock University in St. Catharines, Ontario. He completed a postdoctoral fellowship at the University of Alberta with a visiting scientist appointment at the University of Oxford. Gary moved to private industry in 2008, where his research group focused on process development and scale-up of a proprietary bioprocess technology. He then moved to commercial, large-scale biomanufacturing in 2013. Gary joined Cytiva, formerly part of GE Healthcare’s Life Sciences business, and the Centre for Advanced Therapeutic Cell Technologies (CATCT) at CCRM in 2016. He serves as Director of the collaborative facility in Toronto, Ontario with focus on biology support for New Product Introductions, internal technology development projects and contract process development services in cell and gene therapy.
- What’s next for lab-grown human embryos?
- New Hope for Muscle-Related Diseases? Converting skin cells to immature muscle cells spurs changes, study finds
- Scientists develop brain organoids with complex neural activity
- Phase 1 clinical study reveals how stem cells alleviate COPD inflammation in humans
- Volunteers bring “tears of joy” to paralyzed resident by making Miami Beach accessible to all
- UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
- The Tennessee Institute of Regenerative Medicine Gains International Reach With New Partnership
- National Survey IDs Gaps and Opportunities for Regenerative Medicine Workforce
- The Dawn Of A New Era Of Regenerative Medicine: Tissue Engineering Comes Of Age
- The Memphis Institute of Regenerative Medicine Rebrands To Reflect Statewide Reach
- ISS National Lab to Host Session at World Stem Cell Summit on Regenerative Medicine in Low Earth Orbit
- Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
- Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
- Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit
- Non-altered birth cord cells boost survival of critically ill COVID-19 patients, study shows